Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry מאת A. Selvarajah, A. H. Tavenier, W. L. Bor, V. Houben, S. Rasoul, E. Kaplan, K. Teeuwen, S. H. Hofma, E. Lipsic, G. Amoroso, M. A. H. van Leeuwen, J. M. ten Berg, A. W. J. van ‘t Hof, R. S. Hermanides

קבל טקסט מלא